{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-067031","form_type":"8-K","ticker":null,"cik":"0001750019","company_name":"TCR2 THERAPEUTICS INC.","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.372551+00:00","generated_at":"2026-06-14T09:35:15.601170+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"TCR2 completes merger with Adaptimmune; shareholders receive 1.5117 ADSs per share","bullets":["Each TCR2 share exchanged for 1.5117 Adaptimmune ADSs; options and RSUs converted to Adaptimmune equity awards.","TCR2 to delist from Nasdaq; plans to file Form 25 and Form 15 to suspend SEC reporting obligations.","All directors resigned; Garry Menzel, Andrew Allen, Priti Hegde appointed to Adaptimmune board; Menzel resigned as TCR2 CEO.","Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated By-Laws adopted.","TCR2 becomes indirect wholly-owned subsidiary of Adaptimmune; change in control effective June 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-067031","json":"https://secwatch.observer/filing/0001104659-23-067031.json","markdown":"https://secwatch.observer/filing/0001104659-23-067031.md","text":"https://secwatch.observer/filing/0001104659-23-067031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/tm2317482d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:35:15.601170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"032c873b55","claim":"Garry Menzel resigned as President and Chief Executive Officer at TCR2 THERAPEUTICS INC..","evidence_excerpt":"Garry Menzel, TCR 2 ’s President and Chief Executive Officer, resigned from his position as an officer of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"258cace837","claim":"Andrew Allen was appointed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"Garry Menzel, Andrew Allen and Priti Hegde were each appointed to the board of directors of Adaptimmune","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"31033f6d81","claim":"Shawn Tomasello departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4fa211794b","claim":"Priti Hegde departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"53bcfb2d1a","claim":"Stephen Webster departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"765c29631f","claim":"Garry Menzel departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9ad751a746","claim":"Ansbert Gadicke departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9b6277d16d","claim":"Axel Hoos departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"aa5759b123","claim":"Garry Menzel was appointed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"Garry Menzel, Andrew Allen and Priti Hegde were each appointed to the board of directors of Adaptimmune","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"aeab0c15b8","claim":"Andrew Allen departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ccd83dba20","claim":"Neil Gibson departed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"each of Garry Menzel, Andrew Allen, Priti Hegde, Ansbert Gadicke, Axel Hoos, Neil Gibson, Shawn Tomasello and Stephen Webster ceased serving as directors of TCR 2","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f038b81300","claim":"Priti Hegde was appointed as Director at TCR2 THERAPEUTICS INC..","evidence_excerpt":"Garry Menzel, Andrew Allen and Priti Hegde were each appointed to the board of directors of Adaptimmune","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"525f13e336ca1854e9293e3206d50ffbd05b2e21","claim":"TCR2 THERAPEUTICS INC.: Certificate of incorporation amended and restated to be the same as Merger Sub's certificate of incorporation in connection with the merger.","evidence_excerpt":"TCR 2 ’s third amended and restated certificate of incorporation was further amended and restated to be the same as the certificate of incorporation of Merger Sub, as in effect immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"9a36eae0cdd1f45d95b18ef70f8d44a225130070","claim":"TCR2 THERAPEUTICS INC.: Amended and restated by-laws to be the same as Merger Sub's by-laws in connection with the merger.","evidence_excerpt":"TCR 2 ’s amended and restated by-laws were further amended and restated to be the same as the by-laws of Merger Sub, as in effect immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}